Blood filter hope for preeclampsia: new study explores protein removal to extend pregnancy

NCT ID NCT06464159

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is collecting blood samples from 100 pregnant women with and without preeclampsia to measure key proteins involved in the condition. The goal is to better understand the angiogenic imbalance that causes symptoms and to develop a device that filters out harmful proteins from the blood. If the approach works, it could help women with preeclampsia carry their pregnancies longer, reducing risks from premature delivery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could point toward a new treatment for preeclampsia that removes harmful proteins from the blood, potentially prolonging pregnancy and reducing premature births.
What could go wrong: This is an early-stage observational study focused on collecting data, not testing a treatment. The proposed apheresis therapy is still in development and may not prove effective or safe in future trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREECLAMPSIA

Contacts and locations

Locations

Maternité Port-Royal
RECRUITING

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.